Federal contract award
W81XWH15C0128
IGF::OT::IGF PHASE 2 CLINICAL TRIALS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | W4PZ USA MED RSCH ACQUIS ACT |
| NAICS | 541712 |
| PSC | AD22 — SERVICES - APPLIED RESEARCH/EXPLORATORY DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $10.1M |
| Current contract value | $12.1M |
| Potential contract value / ceiling | $34.6M |
| Start date | Sep 14, 2015 |
| Current end date | Jun 13, 2023 |
| Potential end date | Jun 13, 2023 |
| Latest award activity | Aug 17, 2020 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Oct 22, 2020 | P00007 | $0 | PHASE 2 CLINICAL TRIALS |
| Aug 17, 2020 | P00006 | $-2.0M | PERFORMANCE OF GOOD CLINICAL PRACTICES (GCP) COMPLIANT PHASE 2 CLINICAL TRIAL OF A VALPROIC ACID PRODUCT FOR TREATMENT OF PATIENTS WITH SIGNIFICANT HEMORRHAGE |
| May 5, 2020 | P00005 | $0 | PERFORMANCE OF GOOD CLINICAL PRACTICES (GCP) COMPLIANT PHASE 2 CLINICAL TRIAL OF A VALPROIC ACID PRODUCT FOR TREATMENT OF PATIENTS WITH SIGNIFICANT HEMORRHAGE |
| Mar 20, 2019 | P00004 | $0 | EXTEND BASE PERIOD OF PERFORMANCE, CHANGE REGULATORY SPONSOR FROM GOVERNMENT TO CONTRACTOR FOR VALPROIC ACID PRODUCT FOR TREATMENT OF PATIENTS WITH SIGNIFICANT HEMORRHAGE. |
| Sep 13, 2018 | P00003 | $0 | BASE PERIOD NO-COST EXTENSION |
| Apr 20, 2018 | P00002 | $0 | REVISE STATEMENT OF WORK AT NO-ADDITIONAL COST TO THE GOVERNMENT FOR PHASE 2 CLINICAL TRIALS ASSOCIATED WITH VALPROIC ACID PRODUCT. |
| May 25, 2016 | P00001 | $0 | IGF::OT::IGF PHASE 2 CLINICAL TRIALS |
| Sep 10, 2015 | 0 | $12.1M | IGF::OT::IGF PHASE 2 CLINICAL TRIALS |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.